Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)

Journal:

PLOS Medicine

Published:

2025-05-14

DOI:

10.1371/journal.pmed.1004472

Affiliations:

15

Authors:

18

Go to article

Institutions	Authors	Share
Innomedica Holding AG, Switzerland	7.500000	0.42
University of Bern (UniBE), Switzerland	2.000000	0.11
Neurologisches Institut Konolfingen, Switzerland	2.000000	0.11
Limites Medical Research Ltd., Switzerland	1.000000	0.06
University of Basel (UB), Switzerland	1.000000	0.06
AP-HP Pitié-Salpêtrière Hospital, France	1.000000	0.06
Swiss Paediatric Oncology Group, Switzerland	0.500000	0.03
University Children's Hospital of Zurich, Switzerland	0.500000	0.03
University of Lucerne (UNILU), Switzerland	0.500000	0.03
Hospital St. Anna, Switzerland	0.500000	0.03
Swiss Group for Clinical Cancer Research (SAKK), Switzerland	0.500000	0.03
Università della Svizzera Italiana (USI), Switzerland	0.333333	0.02
Neurocenter of Southern Switzerland (NSI), Switzerland	0.333333	0.02
Ente Ospedaliero Cantonale (EOC), Switzerland	0.333333	0.02

Interested in Neurosciences?